GALT

SEC source: 0001133416-26-000008 · form4.xml · nonDerivative · entry 3

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 870,290

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,968

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 3

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,446

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000010 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 776,260

F1 · security: Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026.

F3 · shares: Represents shares withheld from issuance to Mr. Lewis (but not sold) for federal and state withholding taxes on income.

F2 · balance_after: Represents shares underlying DSUs and Common Stock.

SEC source: 0001133416-26-000008 · form4.xml · derivative · entry 6

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 84,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

F5 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F5 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F5 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

SEC source: 0001133416-26-000008 · form4.xml · nonDerivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 898,021

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000008 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 916,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,700

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

SEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,945

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

SEC source: 0001133416-26-000006 · form4.xml · derivative · entry 5

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

F4 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

SEC source: 0001133416-26-000004 · form4.xml · derivative · entry 5

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

F4 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

SEC source: 0001133416-26-000002 · form4.xml · derivative · entry 3

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,625

Underlying: Common Stock · 8,500 shares

Expires 2035-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.

SEC source: 0001133416-26-000002 · form4.xml · nonDerivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-26-000002 · form4.xml · nonDerivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000081 · form4a.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,269

SEC source: 0001133416-25-000080 · form4a.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,269

SEC source: 0001133416-25-000078 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,382

SEC source: 0001133416-25-000075 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,269

SEC source: 0001133416-25-000074 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,382

SEC source: 0001133416-25-000071 · form4.xml · derivative · entry 4

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,171

Underlying: Common Stock · 7,829 shares

Expires 2030-01-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · derivative.exercise_date: The options vested 100% on December 31, 2020.

SEC source: 0001133416-25-000071 · form4.xml · nonDerivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 832,592

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000071 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 840,421

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

SEC source: 0001133416-25-000069 · form4.xml · derivative · entry 7

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 8,500 shares

Expires 2034-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F4 · derivative.exercise_date: The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.

SEC source: 0001133416-25-000069 · form4.xml · derivative · entry 6

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,037

Underlying: Common Stock · 6,364 shares

Expires 2034-03-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027.

SEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 5

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 4

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 3

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,463

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000067 · form4.xml · derivative · entry 4

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vested 100% on December 31, 2022..

SEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 3

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,500

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 2

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,206

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 1

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001493152-25-028303 · ownership.xml · nonDerivative · entry 2

10X Fund, L.P. · CIK 0001453356 · 10% owner

10X Capital Management, LLC · CIK 0001457247 · 10% owner

CZIRR JAMES C · CIK 0001260641 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,614,457

F3 · price: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001133416-25-000064 · form4.xml · derivative · entry 6

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,417 shares

Expires 2028-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.

SEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 4

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,206

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 3

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,623

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000064 · form4.xml · derivative · entry 5

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,417

Underlying: Common Stock · 16,790 shares

Expires 2028-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.

SEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 2

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,206

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 1

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 22

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,210

Underlying: Common Stock · 16,790 shares

Expires 2028-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F11 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.

SEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 15

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,206

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F12 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.31. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 14

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 21

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F6 · derivative.exercise_date: The options vested 100% on December 31, 2023.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 20

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-03-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F5 · derivative.exercise_date: The options vested 100% on December 31, 2024.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 19

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F5 · derivative.exercise_date: The options vested 100% on December 31, 2024.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 18

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common stock · 20,000 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F4 · derivative.exercise_date: The options vested 100% on December 31, 2022.

SEC source: 0001133416-25-000061 · form4.xml · derivative · entry 17

Shlevin Harold H. · CIK 0001557082 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-03-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F3 · derivative.exercise_date: The options vested 100% on December 31, 2021.